Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: a hellenic cooperative oncology group study.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples